Syros Pharmaceuticals (SYRS) Tops Q2 EPS by 2c, Revenues Beat

Syros Pharmaceuticals (NASDAQ: SYRS) reported Q2 EPS of ($0.38), $0.02 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $3.19 million versus the consensus estimate of $1.9 million.

“Despite the unforeseen challenges of recent months, our team at Syros has shown remarkable resiliency, continuing to execute with excellence as we advance our product candidates toward key data readouts and progress earlier-stage research,” said Nancy Simonian, M.D., Chief Executive Officer of Syros. “We completed enrollment in our Phase 2 trial of SY-1425, opened a new combination cohort in treatment-resistant breast cancer patients in our Phase 1 trial of SY-5609, and presented new preclinical data on SY-5609 in colorectal cancer that further highlights CDK7 inhibition as a potentially transformative targeted approach for difficult-to-treat cancers.

Looking ahead, the second half of 2020 promises to be an exciting time for Syros, with planned data readouts for SY-1425 in two RARA-positive AML patient populations and the first clinical data from the Phase 1 trial of SY-5609 in select solid tumor patients. These data will provide valuable insights that will help inform next steps and, hopefully, bring us closer to our vision of building an enduring company with medicines that provide a profound benefit for patients.”

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.

You May Also Be Interested In

• Nanometrics (NANO) Issues Business Update, Reports FY23 Results
• ProPetro Holding (PUMP) Increases Share Repurchase Authorization to $200 million
• SLM (SLM) Tops Q1 EPS by 20c; offers guidance